DoctorEddy Roccati

Senior Research Fellow

Wicking Dementia Research Education Centre

  • Senior Research Fellow
    Wicking Dementia Research Education Centre
  • 6226 4228
  • Wicking Dementia Research and Education Centre, College of Health and Medicine, Liverpool St, Hobart, Tasmania, 7000, Australia

RESEARCH SUMMARy

Dr Eddy Roccati's research expertise is multifaceted. His skills are primarily in epidemiology, public health, neuroscience, biological/digital markers and preventative health. He has worked in clinical settings (Royal Melbourne Hospital, Alfred Hospital), research settings (University of Melbourne, Monash University, Australian Catholic University, Central Queensland University) and with a diverse portfolio of longitudinal epidemiological cohort studies (Tasmanian Healthy Brain Project, Island Study Linking Ageing and Neurodegenerative Disease, Women's Healthy Ageing Project, 45 and Up, Healthy Brain Initiative, European Prevention of Alzheimer's Dementia). 

 

Eddy has published over 50 peer-reviewed publications (another 4 currently under review) and has been cited over 500 times since 2020 (h-index: 14, i10: 17). His systematic review and meta-analysis linking diet with biomarkers of ADRDs has been cited over 130 times. He is an invited reviewer for Alzheimer’s & Dementia, Frontiers in Aging Neuroscience, BMC Geriatrics, Gerontologist and many more high-impact journals. Eddy has presented at over 30 national and international conferences. Most recently he presented novel findings from ISLAND at the Alzheimer’s Association International Conference 2024 (AAIC) in Philadelphia, USA. Eddy Roccati was also the only Australian recipient of the 2017 Alzheimer's Association International Society to Advance Alzheimer's Research and Treatment (ISTAART) Student Ambassador Award. He remains a mentor for future ISTAART Student Ambassadors. Eddy has received numerous awards for his research achievements. In 2022, Eddy led Wicking Dementia Centre’s team in the International NeuroToolKit Hackathon run by the Alzheimer’s Disease Data Initiative (ADDI), receiving first prize for Patient Value and Clinical Impact. Following this, Eddy Roccati led an international collaboration investigating dementia biomarkers for modifiable risk criteria that is published open-access in Frontiers.

 

Dr Roccati has an established track of research funding in dementia prevention through early detection and intervention. Eddy is a Chief Investigator (CI) on a successful NHMRC Ideas Grant (The future in our hands: Screening for preclinical Alzheimer’s disease by analysing hand movements, $899,792), CI on a RHHRF (Development of a non-invasive screening test to detect risk of Alzheimer’s disease pathology, $446,957) and CIA on an internal UTAS College of Health and Medicine small grants program (Investigating the impact of COVID-19 on blood-based biomarkers, $10,000). He is also CIA on a 2025 Dementia Australia Research Foundation Project Grant (Co-designing an interactive online dashboard to communicate biological and digital markers of dementia risk, $85,000). Eddy has received travel scholarships to present his work at international conferences (such as a $5000 Dementia Centre for Research Collaboration Travel Grant to attend AAIC) and a PhD scholarship from the Australian Government.

FUNDED PROJECTS

  • GRANT
    Co-designing an interactive online dashboard to communicate biological and digital markers of dementia risk
    1 Mar 2025 - 1 Mar 2027
    People funded by this grant:
    • Roccati E,
    • Alty J,
    • King A,
    • Vickers J
    Project Total: $85,000; Every Australian deserves to age well. Dementia is a considerable threat to quality of life and is set to become the leading cause of death in Australia, yet we are not harnessing existing evidence for dementia risk reduction effectively. We know around 40% of dementia cases can be prevented by addressing modifiable risk factors and we know that individuals respond stronger to personal information than aggregated evidence. We know that individuals in longitudinal research projects benefit from receiving personal information, such as digital and biological markers that are indicators of dementia risk, yet we still dont know the best method of presenting this information. This project aims to bridge the gap between knowledge and practice by understanding how people respond to their digital and biological markers of dementia. We will co-design an online dashboard in which to present personal information, alongside personalized evidence-based information to empower individuals to take steps toward positive behavior change. We will engage qualitative (focus groups with community stakeholders, clinicians, participants, researchers, people living with dementia and their caregivers) and quantitative methods (A/B and feasibility testing) to ensure the messaging is presented in a safe, user-friendly and ergonomic fashion. We will then test the impact of revealing this information on wellbeing, self-efficacy and adherence to known modifiable risk factors for dementia. By harnessing personal resonance, we can enact positive behaviour change, improve quality of life and ultimately reduce dementia risk, ensuring Australians can live better for longer. Funded by: Dementia Australia Research Foundation Ltd - Grant-Project ($84,815); University of Tasmania.
  • GRANT
    Evaluating tongue strength as a contributing factor to detecting the earliest stage of Alzheimer's disease pathology
    1 Jan 2024 - 31 Dec 2024
    People funded by this grant:
    • Goldberg L,
    • Alty J,
    • Lawler K,
    • Collins J,
    • Roccati E
    Project Total: $9,800; Recent research suggest that rapid speech-like movements may be a sensitive biomarker of early Alzheimers disease pathology. Tongue strength is integral to such movements. In this project, participants tongue strength will be compared to their speech-like movements and to a blood-based biomarker that is definitive for identifying preclinical AD risk. Findings will determine the contribution of tongue strength as a non-invasive, affordable, easily accessible, and objective indicator of potential cognitive decline for adults in the preclinical stage of AD. Funded by: Royal Hobart Hospital Research Foundation - Grant-Incubator ($9,800); University of Tasmania.
  • GRANT
    Development of a non-invasive screening test to detect risk of Alzheimer's disease pathology
    1 Jan 2022 - 28 Feb 2027
    People funded by this grant:
    • Alty J,
    • Goldberg L,
    • Roccati E,
    • Lawler K,
    • Bhagwat A
    Project Total: $446,957; Alzheimer's disease (AD) starts damaging the brain >10 years before memory problems begin. To reduce dementia incidence, we must detect AD earlier so we can target prevention through early clinical trial recruitment and risk reduction (that could prevent 40% cases). With 10,000 available UTAS research participants and 200 patients from RHH and the community, we aim to develop a test to detect early signs of AD by analysing hand- AND speech- movements using a smartphone and machine learning algorithms. Funded by: Royal Hobart Hospital Research Foundation - Grant-Major Project ($446,957); University of Tasmania.
  • GRANT
    The future in our hands: Screening for preclinical Alzheimer's disease by analysing hand movements
    1 Jan 2021 - 31 Dec 2026
    People funded by this grant:
    • Alty J,
    • Vickers J,
    • Bai Q,
    • Bindoff A,
    • Roccati E
    Project Total: $899,782; Global dementia prevalence is rising. Alzheimer's disease (AD), the most common cause, has devastating effects on people's quality of life. AD has a preclinical (pre-AD) period of 10-20 years when brain pathology silently progresses before any cognitive symptoms appear. Current tests for pre-AD are invasive, costly and unsuitable for screening at population level. If we can't identify people with pre-AD, we can't offer them early interventions. This hinders our strategies to reduce AD prevalence. We will develop a new scalable test (HandTest) by combining two innovative ideas: hand-movement tests to detect pre-AD >10 years before cognitive symptoms begin; and computer vision so people can self-test? online at home. This unique approach builds on the recent discoveries that the posterior cingulate cortex (the first brain region to show abnormalities in pre-AD) is involved in hand-movement control, and that hand-movement patterns change in pre-AD. We will use exquisitely precise computer vision methods to automatically analyse movement data from thousands of participants, who complete the online test by simply opening and closing their hands repeatedly for 5 minutes in front of a standard computer, tablet or smartphone camera. The CI/AI team of experts in hand-movement analysis, pre-AD, computer vision, AD biomarkers and biostatistics has access to 3 well-phenotyped cohorts, >10,000 existing participants and a cutting-edge assay for a blood AD biomarker, ptau181. We will develop a HandTest algorithm to classify hand-movement data for pre-AD risk. In a longitudinal cohort we will determine HandTest's precision to prospectively predict 5-year risks of cognitive decline and AD. This is the critical first step for up-scaling HandTest nationwide via memory clinics of the Australian Dementia Network. With worldwide access to computers, tablets and smartphones increasing, HandTest is scalable globally, potentially transforming dementia prevention and management. Funded by: National Health & Medical Research CouncilNational Health & Medical Research Council - Grant-Ideas ($1,799,564); University of Tasmania.